REF-1588 · Poolton et al., 2026 · Acta Orthopaedica Belgica · Paper · PubMed

A registered systematic review found only three human studies of BPC-157 (30 people: knee injections, bladder instillation and a 2-person intravenous safety pilot), all uncontrolled and judged of poor quality, with very low certainty of evidence

So there is no controlled human evidence that the peptide heals injuries or that it is safe, and the authors advise against using it outside regulated trials; from the abstract

Main caveat: Written from the abstract (no open-access copy in Europe PMC); the search and appraisal could not be checked.
moderate evidenceMeasured on non-athletesRead from the abstract only

Poolton and colleagues searched four databases up to 1 June 2026 for any human study of BPC-157, a synthetic 15-amino-acid peptide, for orthopaedic or regenerative use.

Three studies with 30 participants met the criteria: a retrospective study of knee injections for knee pain, a retrospective pilot of bladder instillation for interstitial cystitis, and a prospective pilot of intravenous safety.

All reported symptom improvement in most participants and no treatment-related adverse events, but all were judged of poor methodological quality, and GRADE certainty was very low because of risk of bias, indirectness and imprecision. The authors conclude that the peptide should not be given to patients except inside approved, regulated, high-quality clinical trials.

Participants

Three studies, n = 30: knee pain, intra-articular injection (n = 16, retrospective); interstitial cystitis, intravesical use (n = 12, retrospective pilot); intravenous safety (n = 2, prospective pilot). No athletes.

Protocol

Eligibility: quantitative or qualitative studies of BPC-157 for any indication in humans.
Appraisal: NIH quality tool for uncontrolled before-after studies; GRADE for certainty.
Synthesis: narrative (SWiM); no pooling.

Key Results

StudyDesignnReported outcome
Knee painretrospective, uncontrolled16symptom improvement in most; no treatment-related adverse events
Interstitial cystitisretrospective pilot, uncontrolled12symptom improvement in most; no treatment-related adverse events
Intravenous safetyprospective pilot2symptom improvement in most (the abstract says this of all three); no treatment-related adverse events
Methodological quality: poor in all three.
Certainty of evidence (GRADE): very low (serious risk of bias, indirectness, imprecision).

Practical Application

Which peptides work? For BPC-157, a 2026 systematic review found no controlled human trial at all — three uncontrolled patient studies in 30 people, judged poor quality, very low certainty — so its benefit and its safety in people are unknown, and the authors say it should not be used outside regulated trials; no athletes were studied.
Inference, not tested here: "no treatment-related adverse events" in 30 uncontrolled patients is not evidence of safety; rare or delayed harms, or harms from impure products, would not show in samples this small.
This review does not address anti-doping status: a tested athlete checks the current WADA Prohibited List before using any product (base practice).
For a sore tendon or an overuse injury the base's route is load management and graded rehabilitation, with red flags to a clinician (SYNTH-73).

Limitations

Written from the abstract (no open-access copy in Europe PMC); the search and appraisal could not be checked.
Only three studies, all uncontrolled, two retrospective; no athletes; no musculoskeletal injury trial.
Animal work, which the authors say makes up most of the evidence, is outside this review.
How this entry was checked and changed
Why this level

a registered review whose abstract reports its quality appraisal and GRADE (poor quality, very low certainty), which the rubric would allow up to A-; held at B+ because it contains no controlled study, so it can show only that controlled human evidence is absent. Any efficacy or safety reading of its three uncontrolled studies would be B- at best